Cassava Sciences – Consensus Indicates Potential 146.9% Upside

Broker Ratings

Cassava Sciences with ticker code (SAVA) now have 3 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 24 and 14 calculating the mean target price we have 19.33. Given that the stocks previous close was at 7.83 this indicates there is a potential upside of 146.9%. The 50 day MA is 8.38 while the 200 day moving average is 6.22. The market cap for the company is $265m. Company Website: http://www.cassavasciences.com

Cassava Sciences, a clinical stage biotechnology company, develops drugs for nervous system disorders. Its lead therapeutic product candidate is PTI-125, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer’s disease. The company was formerly known as Pain Therapeutics and changed its name to Cassava Sciences in March 2019. Cassava Sciences was founded in 1998 and is based in Austin, Texas.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit

AIM All Share Index